1338090-97-3

Upstream product

• 589-87-7 1,4-bromoiodobenzene 
• 439948-91-1 (S)-4-Methyl-2,2-dioxo-[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 
• 950852-76-3 tert-butyl (4S)-4-methyl-2-oxido-1,2,3-oxathiazolidin-2-ium-3-carboxylate 
• 6186-22-7 4-bromophenyl acetone 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 7-phenyl-2-aminoquinoline compounds that are shown to inhibit the biological activity of neuronal nitric oxide synthases (nNOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

Ring opening of cyclic sulfamidates with bromophenyl metal reagents: Complementarity of sulfamidates and aziridines

Bromophenyl magnesium reagents generated via a Knochel type magnesium-halogen exchange of aryl iodides undergo regioselective ring opening of cyclic primary and secondary N-Boc sulfamidates in good to excellent yields. With secondary sulfamidates the reaction proceeds with clean inversion of the stereochemistry. This protocol complements the ring opening of aziridines with bromophenyl metal reagents and extends its scope to secondary substrates.